Compare Recursion Pharmaceuticals Inc (RXRX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 2.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Uranium Energy Corp for 37 Days on average.
| RXRX | UEC | |
|---|---|---|
Market Cap | $2.14B | $4.53B |
Volume | 30,789,535 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $6.79 | $20.14 |
52-Week Low | $2.84 | $9.04 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $1.66B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
UEC trades at $9.24, down 2.43% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of -$87.66M in 2025, with revenue of $66.84M and a deeply negative net income margin of -368.62%. Recent news highlights operational expansion to two mines, but earnings misses in Q1 and Q2 2026 raise concerns about sustainability despite a Q4 beat.
Wall Street analysts remain bullish with an 87.5% buy rating and a $16.06 consensus price target, citing U.S. uranium demand growth. However, high cash burn, reliance on financing, and unproven production sustainability pose significant risks. The stock offers speculative upside if operational execution improves, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
